Multinational Suitors Queue Up As India's Paras Pharma Valuation Shoots Above $1 Billion
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As prospective multinational suitors queue up to clinch a majority equity stake in Paras Pharma - a fast-growing Indian OTC and cosmetic company - leading investment bankers have questioned whether the asking price is "unreasonable and exaggerated.
You may also be interested in...
Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up
MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years
Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up
MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years
J&J Ties Up With India's Emcure For a Splash Into Branded Generics; Deal May Be Precursor To Bigger Global Presence
MUMBAI - It may be a small start in India but the drugs-to-diagnostics giant Johnson & Johnson looks set for a big splash in branded generic drugs - a segment its bigger rivals like Pfizer, GlaxoSmithKline and Sanofi-Aventis have been embracing over the last few years through aggressive partnerships and acquisition of strong regional players